Drug
Inclisiran Sodium IN
Inclisiran Sodium IN: highest development phase Phase 3, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL NCT05739383 | Phase 3 | Primary Prevention of Atherosclerotic Cardiovascular Disease |
Latest
No recent events.
Follow Inclisiran Sodium IN on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.